Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Cash flows from operating activities:
Net income			$ 35,116	$ 31,471
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for credit losses	$ 200		600	200	$ (800)
Depreciation and amortization of premises and equipment			1,182	1,122
Amortization of intangibles	1,273	1,475	2,571	2,975
Net accretion of securities			(2,092)	(1,849)
Amortization of stock-based compensation			1,035	1,093
Accretion of purchase accounting valuations			(1,657)	(2,357)
Net change in deferred loan fees and costs			(362)	(106)
Change in fair value of MSR and other investments			(660)	84
Loss from sale and disposal of premises and equipment			32	174
Net gain on sale of OREO and valuation allowance	(159)	(461)	(159)	(508)
Proceeds from sales of mortgage loans			60,082	43,345
Originations of mortgage loans held for sale			(61,590)	(42,111)
Gain on sales of mortgage loans	(338)	(277)	(672)	(496)
Realized loss on sale of securities				34
Undistributed income of Ansay joint venture			(2,334)	(2,358)
Net earnings on life insurance			(688)	(817)
Increase in other assets			(1,210)	(1,129)
Decrease in other liabilities			(11,172)	(12,504)
Net cash provided by operating activities			18,022	16,263
Cash flows from investing activities:
Activity in securities available for sale and held to maturity: Sales				10,206
Activity in securities available for sale and held to maturity: Maturities, prepayments, and calls			263,608	91,444
Activity in securities available for sale and held to maturity: Purchases			(202,752)	(93,687)
Net increase in loans			(61,919)	(82,384)
Dividends received from Ansay			1,268	1,066
Proceeds from sale of OREO			900	1,936
Proceeds from life insurance			1,899	1,205
Proceeds from sale of premises and equipment			1	2,380
Purchases of premises and equipment			(5,774)	(1,985)
Net cash used in investing activities			(2,769)	(69,819)
Cash flows from financing activities:
Net decrease in deposits			(65,658)	(32,933)
Net decrease in securities sold under repurchase agreements				(75,747)
Proceeds from advances of notes payable				102,000
Repayment of notes payable			(25,508)	(47,000)
Repayment of junior subordinated debentures				(4,124)
Dividends paid			(43,639)	(7,052)
Proceeds from sales of common stock			591	120
Repurchase of common stock			(22,043)	(30,226)
Net cash used in financing activities			(156,257)	(94,962)
Net decrease in cash and cash equivalents			(141,004)	(148,518)
Cash and cash equivalents at beginning of period			261,332	247,468	247,468
Cash and cash equivalents at end of period	$ 120,328	$ 98,950	120,328	98,950	$ 261,332
Cash paid during the year for:
Interest			37,256	30,608
Income taxes			6,669	6,286
Supplemental schedule of noncash activities:
MSR resulting from sale of loans			706	488
Change in unrealized gain (loss) on investment securities available for sale, net of tax			$ 1,590	$ (625)